ABSTRACT
The primary clinically relevant subsets of breast cancers are estrogen receptor (ER)-positive and ER-groups, with progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status also playing a significant role in clinical management. The College of American Pathologists (CAP) and American Society of Clinical Oncology (ASCO) define ER+ tumors as tumors expressing ER (by immunohistochemistry) in 1% or more of the tumor cells. 1 This low bar is set based on studies showing a beneficial response to antiestrogen therapy in such cancers. 2 It has been recognized over the years that semiquantitative ER results provide more information than a mere positive and negative result, and ASCO/CAP also recommends providing semiquantitative results. 1, 3 However, there are only limited data on the clinical usefulness of semiquantitative hormone receptor results. A few studies have shown an increasing benefit of hormonal therapy with an increasing degree of ER expression. 4 Semiquantitative hormone receptor results are now also used in multivariable models to provide additional information regarding chemotherapy benefit. [5] [6] [7] [8] Availability of semiquantitative results for ER allows us to explore the possibility that weakly or low ER+ tumors form a distinct subgroup. A few studies have shown that tumors with ER expression in less than 10% cells likely behave like ER-tumors. [9] [10] [11] [12] We have also shown that the morphologic features of low ER+ tumors are similar to the morphologic features of ER-tumors. 13 In this study, we have evaluated the pathologic response to neoadjuvant chemotherapy in low ER+ tumors and compared it with ERtumors, moderately ER+ tumors, and high ER+ tumors. We have further explored the differences in recurrence rate and survival with respect to the degree of ER expression.
Materials and Methods
After institutional review board approval from the University of Pittsburgh, a retrospective review of a prospectively maintained database was conducted on 614 patients who received neoadjuvant therapy from 2010 to 2014 at Magee-Womens Hospital of the University of Pittsburgh Medical Center. The following exclusion criteria were applied for case selection: lack of semiquantitative ER H-score, cases that received neoadjuvant hormonal therapy only (the majority of such cases were strongly ER+), and unequivocally HER2+ cases. The unequivocal HER2+ refers to cases with an immunohistochemical score of 3+ or fluorescence in situ hybridization amplified (by 2013 ASCO/CAP criteria) if the immunohistochemical score was 2+. After excluding these cases, 327 remaining cases formed the basis of this study. Patient charts were reviewed, with respect to pathology report, operative report, chemotherapy regimen, and clinical outcomes. ER+ patients received hormonal therapy after surgery in addition to the neoadjuvant chemotherapy, and ER-patients received only neoadjuvant chemotherapy as per standard protocol.
Pathologic complete response (pCR) was defined as the absence of invasive tumor in the breast resection specimen and regional lymph nodes. Residual in situ carcinoma was allowed. In addition to pCR, estimated tumor size/volume reduction in the breast was calculated using the following equation: estimated percent tumor size/volume reduction = [(pretherapy clinical size -"revised" pathology size)/pretherapy clinical size] * 100. The "revised" pathology tumor size is calculated by multiplying the largest dimension of the gross tumor bed by the invasive tumor cellularity of the tumor bed in comparison to the pretherapy core biopsy sample.
14 Although our institution now uses the international working group recommended residual cancer burden method, such information was not available for the cases used in this study. 15 Hormone receptor values were reported using the semiquantitative histochemical or H-score method. This system is a sum of percent staining multiplied by intensity score (0 = absent, 1 = weak, 2 = moderate, 3 =strong), with the resulting score ranging from 0 to 300. 16, 17 Estrogen receptor values were grouped into four categories for the purposes of our analysis: ER-(H-score = 0), low ER+ (H-score 1-100), moderate ER+ (H-score 101-200), and high ER+ (H-score 201-300). ❚Image 1❚ shows examples of the different categories. Groups were analyzed for overall pathologic complete response, tumor volume reduction, nodal status, and disease-free and overall survival. Mean follow-up time was 33.6 months (median, 31.6 months; range, 7.5-70.3 months). Kaplan-Meier survival curves for disease-free survival and overall survival were analyzed with respect to ER levels, and P values were obtained using the log-rank test.
Statistical analysis was performed using the R Project for Statistical Computing (Vienna, Austria). For continuous variables, the P value was obtained from the twosided Wilcoxon rank-sum test. For categorical variables, the P value was obtained from the two-sided Fisher exact test. Patients with missing/unknown information were excluded from the test. Confidence intervals were obtained from Wald normal approximation. Logistic regression was performed to predict pCR within ER+ tumors. Prediction performance of ER status, Magee Equation 3 (ME3), 6, 7 and their combination were compared by area under the curve (AUC) analysis.
Results
Of the 327 patients eligible for this study, there were 141 (43%) patients in the ER-group, 41 (13%) in the low ER group, 47 (14%) in the moderate ER group, and 98 (30%) in the high ER group. The pCR rates of ER-, low ER+, moderate ER+, and high ER+ tumors were 25.5%, 36.6%, 10.6%, and 4.1%, respectively ❚Table 1❚. The pCR rate of low ER+ tumors was similar to that of ER-tumors (P = .1722) and significantly different from moderate (P = .0049) and high ER+ tumors (P < .0001). In addition to pCR, tumor size/volume reduction in the breast was also evaluated. The tumor size/volume reduction of 78% in low ER+ tumors was similar to the average size reduction in ER-tumors (70% average size reduction, P = .2358) and moderate ER+ tumors (71%, P = .3518) but was significantly different from the size reduction in high ER+ tumors (58%, P = .0012). Furthermore, each group was compared with the low ER+ group with respect to patient and tumor characteristics ❚Table 2❚, ❚Table 3❚, and ❚Table 4❚. No statistically significant differences were identified between ER-and low ER+ tumors ( Table 2 ). The patients with moderately ER+ tumors were slightly younger and more frequently premenopausal compared with the low ER+ tumor group (Table 3) . The moderately and high ER+ tumors were more frequently PR+, showed higher PR H-scores, had a lower pretherapy nuclear grade, and had a lower Ki-67 labeling index compared with the low ER+ group (Tables 3 and 4 ). The high ER+ tumors were also more frequently of the lobular phenotype and showed a significantly higher number of white patients compared with the low ER+ tumors (Table 4) . Since the prior studies define low ER as 1% to 10% ER+ cells, we also examined the pCR rate of tumors with H-scores 1 to 10 and 11 to 100. Of the 41 low ER+ tumors, 27 (66%) had H-scores 1 to 10 and 14 (34%) had H-scores 11 to 100. Nine (33%) of 27 tumors with H-scores 1 to 10 showed pCR compared with six (43%) of 14 tumors with H-scores 11 to 100 (P = .7337).
Recurrence and survival data were available and are reported separately for patients who achieved pCR and those who did not. Of the 60 patients who achieved pCR, there was only one distant recurrence (recurrence rate of 3%) and one death during follow-up, with a survival rate of 97%. The single recurrence and death occurred in the ER-group.
Among the 267 patients with residual disease after neoadjuvant chemotherapy, there were 66 (25%) recurrences, of which 56 (20%) were distant. There were 38 deaths, with an overall survival rate of 85%. The recurrence and death rate of low ER+ tumors were similar to the recurrence and death rate of ER-tumors but significantly different from the recurrence and death rate of moderate ER+ tumors and high ER+ tumors ❚Table 5❚; ❚Figure 1❚ and ❚Figure 2❚. The difference in recurrence and death rate between low ER+ and other ER+ tumors was significant particularly within the posttherapy lymph node-positive subgroup ❚Table 6❚ and ❚Table 7❚. Logistic regression AUC analysis showed ER status predicts for pCR (AUC = 0.77); however, the ME3 model is even more predictive, with an AUC of 0.82 ❚Figure 3❚.
Discussion
It is well known that breast cancer is a heterogeneous disease on the morphologic, immunohistologic, and molecular level. The different phenotypes express varying clinical behaviors. ER status is what distinguishes luminal breast cancer from other phenotypes. Approximately 70% to 75% of breast cancers are ER+, with a slightly higher percentage positivity seen in white and elderly populations and slightly lower in nonwhite and younger populations. 18, 19 Often, not much attention is paid to the degree of ER positivity, and this additional useful information is frequently lost in large clinical trials where the tumor groups are only referred to as ER+ and ER-. The semiquantitative scores for hormone receptors appear to be important for judging response not only to endocrine therapy but also to chemotherapy. These semiquantitative immunohistochemical scores are often part of the multivariable models to predict for chemotherapy response. [5] [6] [7] [8] Expensive multigene assays are also available to predict for chemotherapy benefit and frequently use quantitative hormone receptor gene expression levels for their predictive scores. 20, 21 In this study, we investigated the clinical usefulness of semiquantitative ER scoring by immunohistochemistry. We identified a group of ER+ tumors that have a distinct phenotype and response to neoadjuvant chemotherapy. In addition, we have also compared the patient and tumor characteristics of low ER+ tumors with other ER+ tumors and ER-tumors.
Comparison of tumor and patient characteristics of low ER+ and ER-tumors showed no statistically significant differences (Table 2 ). These findings indicate close similarity between low ER+ and ER-tumors. Comparison of tumor and patient characteristics of low ER+ and moderately ER+ tumors showed a statistically significant difference in age, menopausal status, semiquantitative PR H-score, PR status, pretherapy nuclear grade, and Ki-67 labeling index ( Table 3 ). The latter four differences confirm the close relationship between the semiquantitative ER H-score with PR H-score, PR status, nuclear grade, and tumor proliferation. The patients with moderately ER+ tumors were surprisingly younger and premenopausal. However, this aberration could be due to some selection bias for neoadjuvant chemotherapy in ER+ tumors. Comparison of tumor and patient characteristics of low ER+ and strongly ER+ tumors showed statistically significant differences in PR H-score, PR status, Ki-67 labeling index, pretherapy nuclear grade, histology, and race (Table 4) . These statistically significant differences highlight the fact that strongly ER+ tumors are more frequent in white patients, are frequently of the lobular phenotype, have strong PR expression, and are of a lower grade with a low proliferation index. [22] [23] [24] Strongly ER+ tumors appear to be biologically different from low ER+ tumors.
❚Figure 2❚ Overall survival plot of patients with residual disease (no pathologic complete response) (n = 267), categorized by estrogen receptor (ER) status. P value obtained from the log-rank test with low ER+ as a reference. P = .672 for ER-. P = .003 for moderate ER+. P = 0 for high ER+.
❚Figure 1❚ Disease-free survival plot of patients with residual disease (no pathologic complete response) (n = 267), categorized by estrogen receptor (ER) status. P value obtained from the log-rank test with low ER+ as a reference. P = .657 for ER-. P = .025 for moderate ER+. P = .006 for high ER+. 12 evaluated the effect of endocrine therapy and survival outcome in 1,257 patients previously classified as triple negative. Upon review, the tumors were classified as ER less than 1%, 1% to 5%, and 6% to 10% positive cells. The prognosis of the tumors with low ER expression, especially 1% to 5%, did not differ significantly from tumors with undetectable levels of ER. We have broadened the prior definitions by using an H-score of 1 to 100 to define low ER+ tumors. Since H-score takes into account both intensity of staining and percentage of positive cells, an H-score of 1 to 100 includes not only tumors with 1% to 10% positive cells but also tumors with more than 10% positive cells, often with weak intensity staining. In our prior study, we have taken the same cutoff (H-score of 1-100) to define the morphologic features of such tumors. The morphologic features of tumors with H-scores of 1 to 100 show similarity to triple-negative tumors with medullary/atypical medullary features and a high proliferation index. 13 Our current study is focused on the response of such tumors to neoadjuvant chemotherapy. Our results indicate a high pCR rate for low ER+ tumors. Since the prior studies define low ER as 1% to 10% ER+ cells, we also examined the pCR rate of tumors with H-scores 1 to 10 and 11 to 100. No statistically significant difference was identified between the two groups of low ER+ tumors (see results above). As far as response to chemotherapy is concerned, multivariable models that include quantitative hormone receptor results and Ki-67 proliferation index have been shown to provide chemopredictive information. 6, 8 The multivariable model developed at our institution, the ME3, was more informative than ER status alone in predicting pCR in ER+ tumors (Figure 3) .
The results of our study are very similar to a recently published study by Fujii and colleagues. 25 In a large study of 3,055 ER+/HER2-negative cases, Fujii et al 25 showed a high likelihood of pCR for tumors when ER expression was seen in 1% to less than 10% of the cells. They further showed the benefit of adjuvant hormonal therapy only in patients with ER reactivity in more than or equal to 10% of the tumor cells. Based on their results, Fujii and colleagues 25 questioned the current ASCO/CAP definition of ER positivity.
In summary, low ER+ breast cancers are rare and represent approximately 5% of all breast cancers. 13 Our study is one of the few to evaluate the pCR rate of low ER+ breast cancers. Low ER+ tumors appear to be a distinct ❚Figure 3❚ Logistic regression area under the curve (AUC) predicting pathologic complete response using Magee Equation 3 (ME3) and estrogen receptor (ER) status. ME3 results available on 177 ER+ patients are used for analysis. subset of ER+ tumors that derive substantial benefit from chemotherapy. There are limited data on the benefit of endocrine therapy in such tumors, but future studies should specifically evaluate this subset for endocrine therapy benefit. Many clinical trials for women with triple-negative breast cancers exclude patients with low ER+ tumors. Our data support growing evidence that this subset of patients should be treated differently from those with high ER+ tumors, and this should be taken into consideration for future trial design. We recommend reporting semiquantitative immunohistochemical scores for hormone receptors as these scores ultimately help in therapeutic decision making.
